SCHEMBL14948926

SCHEMBL14948926

CCC[C@H](NC(=O)Nc1ccc(Br)cc1F)C(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 7/20 0.53
ALDH1A1 P00352 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LMNA P02545 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
AAK1 Q2M2I8 3/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
PKM P14618 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
POLB P06746 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29758797 0.89 FPR2 (0.53) FPR2ALDH1A1L3MBTL1LMNANPC1
SCHEMBL14903120 0.87 AAK1 (0.53) FPR2ALDH1A1L3MBTL1AAK1
SCHEMBL28109440 0.87 FPR2 (0.48) FPR2ALDH1A1L3MBTL1LMNANPC1
SCHEMBL14948981 0.84 FPR2 (0.50) FPR2ALDH1A1L3MBTL1LMNANPC1
SCHEMBL14948943 0.84 FPR2 (0.50) FPR2ALDH1A1L3MBTL1LMNANPC1
SCHEMBL14937789 0.84 FPR2 (0.65) FPR2ALDH1A1L3MBTL1LMNANPC1
SCHEMBL14948914 0.84 FPR2 (0.65) FPR2ALDH1A1L3MBTL1LMNANPC1
SCHEMBL14948913 0.83 FPR2 (0.58) FPR2ALDH1A1L3MBTL1LMNANPC1
SCHEMBL14902811 0.83 FPR2 (0.58) FPR2ALDH1A1L3MBTL1LMNANPC1
SCHEMBL14948979 0.82 FPR2 (0.72) FPR2ALDH1A1L3MBTL1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3088385-A1 ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2016-11-02 EP disclosed
US-8816076-B2 Aryl urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators ALLERGAN, INC. (US) 2014-08-26 US disclosed
US-8541577-B2 Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators ALLERGAN, INC. (US) 2013-09-24 US disclosed
US-20130123496-A1 ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-05-16 US disclosed
WO-2013070600-A1 ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123496-A1 ARYL UREA DERIVATIVES AS N-FORMYL PEPTIDE RECEPTORS LIKE-1 (FPRL-1) RECEPTOR MODULATORS FPR1, FPR3, FPR2 FPR2 3/4885ALDH1A1 3881/4885L3MBTL1 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.